Skip to Content
Merck
All Photos(1)

Documents

H102

Supelco

Haloperidol metabolite II

analytical standard

Synonym(s):

(±)-4-(4-Chlorophenyl)-α-(4-fluorophenyl)-4-hydroxy-1-piperidinebutanol, Reduced Haloperidol

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H25ClFNO2
CAS Number:
34104-67-1
Molecular Weight:
377.88
MDL number:
MFCD00055102
UNSPSC Code:
41116107
PubChem Substance ID:
329815151
NACRES:
NA.24

grade

analytical standard

Quality Level

100

Assay

≥98% (HPLC)

form

solid

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

color

white

solubility

DMSO: 10 mg/mL

application(s)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

format

neat

SMILES string

OC(CCCN1CCC(O)(CC1)c2ccc(Cl)cc2)c3ccc(F)cc3

InChI

1S/C21H25ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,20,25-26H,1-2,11-15H2

InChI key

WNZBBTJFOIOEMP-UHFFFAOYSA-N

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000361578
0000361578
FN09271904
027M4605V
078K4619

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

D W Eyles et al.
Psychopharmacology, 116(2), 161-166 (1994-10-01)
In patients taking haloperidol (HP), circulating concentrations of reduced haloperidol (RHP increase disproportionately to the dose or concentration of the parent drug. In the current study, we tested the hypothesis that the nonlinearity is due to preferential saturation of the
M S Lee et al.
Psychiatry and clinical neurosciences, 52 Suppl, S193-S198 (1999-01-23)
Along with recent increased interest in the selective serotonin reuptake inhibitors, a number of studies has been undertaken to observe interactions with different drugs. When selective serotonin reuptake inhibitor was administered together with antipsychotics to schizophrenics showing depressive or obsessive
L Pan et al.
European journal of clinical pharmacology, 55(8), 599-604 (1999-12-14)
To investigate in vitro which CYP isoforms (CYP1A2, CYP2D6 and CYP3A4) are involved in the biotransformation of haloperidol (HAL) and reduced haloperidol (RHAL). The biotransformation of HAL and RHAL is evaluated by measuring HAL and RHAL remaining after incubation with
W H Chang et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 4(2), 119-126 (1994-06-01)
Plasma haloperidol (HL) and reduced haloperidol (RH) levels were measured in 60 schizophrenic patients treated with high to very high HL doses of 40-200 mg/day. Plasma samples were obtained at steady-state conditions and 10-12 h after the evening dose and
D W Eyles et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 8(2), 127-129 (1998-06-10)
In vitro, cytosolic human ketone reductases catalyse the stereospecific (i.e. >99%) formation of S(-) reduced haloperidol (RHP) from haloperidol (HP). Whether this situation is reflected in patients taking the drug is unknown. In this study in nine patients taking HP
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service